BioRestorative Therapies, Inc. (BRTX)

1.3650 -0.0850 (-5.86%) At close: 04:00PM EDT

BioRestorative Therapies, Inc.

40 Marcus Drive
Suite 1
Melville, NY 11747
United States
631 760 8100
https://www.biorestorative.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 11

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Lance Alstodt	Chairman of the Board, President & CEO	954.17k	N/A	1971
Mr. Robert Eugene Kristal	Chief Financial Officer	368.12k	N/A	1968
Mr. Francisco J. Silva	Chief Scientist, VP of Research & Development, Secretary and Director	891.67k	N/A	1975
Mr. Robert Paccasassi	Vice President of Quality Assurance & Regulatory Compliance	233.95k	N/A	1969
Dr. Wayne J. Olan M.D.	Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs relate to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is based in Melville, New York.

Corporate Governance

BioRestorative Therapies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.